Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention

about

Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention

Item

http://www.wikidata.org/entity/Q38831064

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Neurocognitive outcomes in neu ...... ns for the domain of attention

@en

type

Item

label

Neurocognitive outcomes in neu ...... ns for the domain of attention

@en

prefLabel

Neurocognitive outcomes in neu ...... ns for the domain of attention

@en

P1476

Neurocognitive outcomes in neu ...... ns for the domain of attention

@en

P2093

Bonita P Klein-Tasman

http://www.w3.org/2001/XMLSchema#string

Claire Semerjian

http://www.w3.org/2001/XMLSchema#string

Heather L Thompson

http://www.w3.org/2001/XMLSchema#string

Jennifer Janusz

http://www.w3.org/2001/XMLSchema#string

Karin S Walsh

http://www.w3.org/2001/XMLSchema#string

Kristina K Hardy

http://www.w3.org/2001/XMLSchema#string

Laura Schaffner Gray

http://www.w3.org/2001/XMLSchema#string

Mary Anne Toledo-Tamula

http://www.w3.org/2001/XMLSchema#string

Nicole Ullrich

http://www.w3.org/2001/XMLSchema#string

Pamela L Wolters

http://www.w3.org/2001/XMLSchema#string

P2860

Effect of simvastatin on cognitive functioning in children with neurofibromatosis type 1: a randomized controlled trial

Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence

A mouse model for the learning and memory deficits associated with neurofibromatosis type I

The MATRICS consensus cognitive battery: what we know 6 years later.

Cognitive impairment in neurofibromatosis type 1.

Behavioral phenotype of neurofibromatosis, type 1.

Lovastatin as treatment for neurocognitive deficits in neurofibromatosis type 1: phase I study.

The effect of methylphenidate on neurofibromatosis type 1: a randomised, double-blind, placebo-controlled, crossover trial.

Psychometric properties of the Vanderbilt ADHD diagnostic parent rating scale in a referred population.

Simvastatin for cognitive deficits and behavioural problems in patients with neurofibromatosis type 1 (NF1-SIMCODA): a randomised, placebo-controlled trial.

P304

S21-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1212/WNL.0000000000002928

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

7 Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Peter De Blank

Jonathan M Payne

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27527646

http://www.w3.org/2001/XMLSchema#string

P932

5578356

http://www.w3.org/2001/XMLSchema#string